

Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies

Guidance for Industry and Food and Drug Administration Staff

Document issued on September 12, 2017.

The draft of this document was issued on June 20, 2016.

For questions about this document regarding CDRH-regulated devices, contact CDRH at 301-796-5900 or CDRHPatientDiversity@fda.hhs.gov or CDRHClinicalEvidence@fda.hhs.gov.

For questions about this document regarding CBER-regulated devices, contact the Office of Communication, Outreach, and Development (OCOD) at 1-800-835-4709 or 240-402-8010.



**U.S. Department of Health and Human Services
Food and Drug Administration**

Center for Devices and Radiological Health

Center for Biologics Evaluation and Research

Preface

Public Comment

You may submit electronic comments and suggestions at any time for Agency consideration to <http://www.regulations.gov> . Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number FDA-2016-D-0734. Comments may not be acted upon by the Agency until the document is next revised or updated.

Additional Copies

CDRH

Additional copies are available from the Internet. You may also send an e-mail request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please use the document number 1500626 to identify the guidance you are requesting.

CBER

Additional copies are available from the Center for Biologics Evaluation and Research (CBER) Office of Communication, Outreach, and Development (OCOD), 10903 New Hampshire Ave., WO71, Room 3128, Silver Spring, MD 20903, or by calling 1-800-835-4709 or 240-402-8010, by email, ocod@fda.hhs.gov, or from the Internet at <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>.

Table of Contents

I.	INTRODUCTION	5
II.	SCOPE.....	6
III.	BACKGROUND.....	7
A.	SECTION 907 OF THE FOOD AND DRUG ADMINISTRATION SAFETY AND INNOVATION ACT (FDASIA)	8
B.	TERMINOLOGY	8
(1)	Age	8
(2)	Race and Ethnicity	9
C.	WHY CONSIDER AGE-, RACE-, AND ETHNICITY-SPECIFIC DIFFERENCES	10
(1)	Age	10
(2)	Race and Ethnicity	11
D.	PARTICIPATION OF AGE-, RACE-, AND ETHNICITY-SPECIFIC SUBGROUPS IN CLINICAL TRIALS	12
(1)	Barriers to Enrollment	12
(2)	Enrollment Resources	13
IV.	RECOMMENDATIONS FOR ACHIEVING APPROPRIATE ENROLLMENT	14
A.	CONSIDERATION OF POTENTIAL AGE-, RACE-, AND ETHNICITY-SPECIFIC DIFFERENCES	15
(1)	Study Design, Early Enrollment Stage	15
(2)	Premarket Submission Stage	16
(3)	Postmarket Submission Stage	16
B.	PLANNING FOR DIVERSE STUDY RECRUITMENT.....	16
(1)	Study Design, Early Enrollment Stage	17
(2)	Premarket Submission Stage	18
(3)	Postmarket Submission Stage	19
C.	CONSIDERATIONS FOR STUDY FOLLOW-UP VISITS	19
V.	CONSIDERING AGE, RACE, AND ETHNICITY IN STUDY DESIGN, ANALYSIS, AND INTERPRETATION OF STUDY RESULTS.....	20
A.	ASSESSING HETEROGENEITY ACROSS AGE, RACIAL, AND ETHNIC SUBGROUPS	21
(1)	Study Design, Early Enrollment Stage	22
(2)	Premarket Submission Stage	22
(3)	Postmarket Submission Stage	23
B.	DESIGNING STUDIES: RECOMMENDATIONS FOR SUBGROUP SPECIFIC STATISTICAL ELEMENTS	23
(1)	Recommendations When Subgroup Differences are Anticipated	24
(2)	Recommendations for Pre-specifying Assessment of Heterogeneity	24
(3)	Additional Design Recommendations for Comparative and One-arm Studies	24
C.	COMPLETED STUDIES: RECOMMENDATIONS FOR ANALYSIS OF SUBGROUP-SPECIFIC DATA.....	25
D.	INTERPRETATION OF AGE-, RACE-, AND ETHNICITY-SPECIFIC DATA	26
VI.	RECOMMENDATIONS FOR SUBMITTING AGE-, RACE-, AND ETHNICITY-SPECIFIC DATA IN SUBMISSIONS TO THE AGENCY AND REPORTING IN PUBLIC DOCUMENTS.....	26
A.	ENROLLMENT DEMOGRAPHICS, BASELINE CHARACTERISTICS & CO-MORBIDITIES	27
(1)	IDE Stage	28
(2)	Premarket Submission Stage	28
(3)	Postmarket Submission Stage	28
B.	AGE-, RACE-, AND ETHNICITY-SPECIFIC OUTCOMES (SAFETY OR EFFECTIVENESS, OR PROBABLE BENEFIT FOR HDEs).....	29

Contains Nonbinding Recommendations

(1) Premarket Submission Stage.....	31
(2) Postmarket Submission Stage	31
APPENDIX 1 – DECISION FRAMEWORK.....	32
FIGURE 1: RECOMMENDATIONS FOR DEMOGRAPHIC SUBGROUP-SPECIFIC STATISTICAL STUDY DESIGN	33
FIGURE 2: RECOMMENDATIONS FOR DEMOGRAPHIC SUBGROUP-SPECIFIC STATISTICAL ANALYSIS FOR ONE-ARM STUDIES (OBJECTIVE PERFORMANCE CRITERION, PERFORMANCE GOAL, OBSERVATIONAL STUDY).....	34
FIGURE 4: RECOMMENDATIONS FOR SUBMITTING AND REPORTING SUBGROUP-SPECIFIC PARTICIPATION AND OUTCOME INFORMATION	36

Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies

Guidance for Industry and Food and Drug Administration Staff

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

The purpose of this guidance is to outline the FDA's expectations and provide recommendations for the evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies. The primary intent of these recommendations is to improve the quality, consistency, and transparency of data regarding the performance of medical devices within specific age, racial, and ethnic groups. Proper evaluation and reporting of this data can benefit patients, clinicians, researchers, regulators, and others. Additionally, it is important that clinical trials include diverse populations that reflect the intended use population. In general, to achieve an unbiased estimate of treatment effect in the general population, sponsors should develop a strategy to enroll diverse populations including representative proportions of relevant age, racial, and ethnic subgroups, which are consistent with the intended use population of the device. This guidance includes recommendations and considerations to assist sponsors in developing such a strategy. FDA recognizes the practical challenges in achieving the appropriate enrollment of diverse populations. This guidance includes recommendations to overcome barriers to enrollment in order to balance these recommendations with least burdensome principles.

This guidance extends the policy set forth in the FDA's *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* Guidance¹ to additional demographic subgroups of age, race, and ethnicity. This guidance also extends and complements FDA's *Collection of Race and*

¹ See FDA's guidance *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf>.

Contains Nonbinding Recommendations

Ethnicity Data in Clinical Trials Guidance, which, for collecting and reporting race- and ethnicity-specific information in clinical trials, recommended the use of the standardized approach developed by the Office of Management and Budget (OMB).²

The specific objectives of this guidance are to:

- 1) encourage the collection and consideration during the study design stage of relevant age, race, ethnicity, and associated covariates (e.g., body size, biomarkers, bone density) for devices for which safety, effectiveness (or, for humanitarian device exemptions (HDEs), probable benefit), or benefit-risk profile is expected to vary across these groups;
- 2) outline recommended analyses of study subgroup data, with a framework for considering demographic data when interpreting overall study outcomes; and
- 3) specify FDA's expectations for reporting age-, race-, and ethnicity-specific information in summaries and labeling for approved or cleared medical devices.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidance means that something is suggested or recommended, but not required.

II. Scope

This guidance is intended for devices that include clinical information in support of a marketing submission, whether a premarket notification (510(k)), premarket approval (PMA) application, evaluation of Automatic Class III Designation (De Novo request), or HDE application. The recommendations contained herein also apply to post-approval study submissions and postmarket surveillance studies, where noted.

Age, race, and ethnicity are not the only demographic variables that may affect device performance. While this guidance focuses on the impact of age, race, and ethnicity, some of the recommendations may also be used to promote study enrollment and data analysis adequately accounting for other demographic variables, such as sex³ and geographic location (e.g., rural). Other patient characteristics, such as emotional, physical, sensory, and cognitive capabilities, can often be important variables when evaluating medical device safety and effectiveness (or probable benefit for HDEs); however, these will not be addressed within this guidance. For further information related to these user considerations please see the FDA's *Design Considerations for Devices Intended for Home Use* Guidance.⁴

² See FDA's guidance *Collection of Race and Ethnicity Data in Clinical Trials* <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-gen/documents/document/ucm126396.pdf>.

³ See FDA's guidance *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf>.

⁴ See FDA's guidance *Design Considerations for Devices Intended for Home Use* <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm331681.pdf>.

Contains Nonbinding Recommendations

The impact of demographic variables on device safety, effectiveness (or probable benefit, for HDEs), or benefit-risk profile may be greater for certain types of products or diseases than others. For example, certain dermatology devices may have different considerations for use in a specific racial or ethnic population. Similarly, certain orthopedic devices may have different considerations for use in specific age groups. Studies of devices intended only for certain groups (e.g., pediatrics) would not be expected to address the potential differences in outcome for groups outside the intended use population. Additionally, some *in vitro* diagnostic (IVD) device clinical studies are conducted on de-identified leftover specimens, so it may not be possible to obtain demographic information, such as age, race, or ethnicity. As a result, evaluation of age-, race-, and ethnicity-specific data would not be possible in these cases. Furthermore, for companion diagnostic devices undergoing accelerated approval, FDA advises sponsors to consult with the primary review Division or Branch.⁵

When clinically relevant differences in treatment effect are anticipated across age, racial, or ethnic groups, it is important to consider proper clinical study design, sufficient enrollment of subgroups to allow meaningful analysis, and controlling of study-wise Type 1 error for overall and subgroup-specific hypothesis testing, if appropriate and feasible.

FDA recommends the use of this guidance document as a supplement to other FDA guidance where applicable, in particular, any relevant device-specific guidance, as well as FDA's *Collection of Race and Ethnicity Data in Clinical Trials* guidance.⁶

III. Background

Certain elements described in this guidance have been emphasized in Agency regulations and/or policy in the past. Over recent decades the Agency's views, as well as those of the medical community in general, have evolved regarding age, race, and ethnicity in clinical studies.

Prior to developing the policy set forth in this guidance, FDA publicly sought input from a variety of experts and stakeholders regarding the study and evaluation of age, race, and ethnicity in clinical studies for medical devices. On April 9, 2015, the Institute of Medicine convened a public workshop of various government agencies, physician professional societies, and patient advocacy groups to discuss strategies for ensuring diversity, inclusion, and meaningful participation in clinical trials.⁷ This guidance document reflects the recommendations generated in this and other public fora. It is intended to provide guidance on the design, conduct, and reporting of clinical studies to improve age-, race-, and ethnicity-specific information about the safety and effectiveness (or probable benefit for HDEs) of approved and cleared new medical devices.

⁵ See FDA's guidance *Requests for Feedback on Medical Device Submissions: The Pre-Submission Program and Meetings with Food and Drug Administration Staff*

<http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm311176.pdf>.

⁶ See FDA's guidance *Collection of Race and Ethnicity Data in Clinical Trials* <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-gen/documents/document/ucm126396.pdf>.

⁷ Institute of Medicine Workshop: Strategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials. April 9, 2015. Agenda and presentations available at <http://iom.nationalacademies.org/Activities/SelectPops/HealthDisparities/2015-APR-09.aspx>.

A. Section 907 of the Food and Drug Administration Safety and Innovation Act (FDASIA)

Section 907 of the Food and Drug Administration Safety and Innovation Act (FDASIA)⁸ directed the Agency to publish and provide to Congress a Report, followed by an Action Plan outlining “recommendations... to improve the completeness and quality of analyses of data on demographic subgroups [including sex, age, race, and ethnicity] in summaries of product safety and effectiveness data [or probable benefit for HDEs] and in labeling;...on the inclusion of such data, or the lack of availability of such data in labeling; [and] to...improve the public availability of such data to patients, health care providers, and researchers.” In that Action Plan, CDRH committed to develop this guidance, as an action to improve the completeness, quality, and public availability of demographic subgroup data from medical device clinical studies.⁹

B. Terminology

(1) Age

When evaluating age-specific data, clinical studies should plan to group subjects by age groups as appropriate for the disease condition. Standardizing age categories may not be appropriate for all devices; however, more discrete age groupings should be considered. For example, you may group older patients for analysis at 65-74 years old, and 75-84 years old, rather than simply older/younger than 65.

FDA does not define a specific age for the geriatric population due to the different considerations for the wide variety of medical devices and diagnostics. However, we recommend stratifying age (e.g. 65-74, ≥ 75 years) based on relevant disease characteristics.

Device regulations define the pediatric population as any patient less than 22 years of age.¹⁰ It should be noted that this may differ from the drug and biologic regulations but, for purposes of this guidance, the definition of pediatric patient in 21 CFR 814.3(s) should be used. This population should be further subdivided

⁸ Food and Drug Administration Safety and Innovation Act, P.L. 112-144, July 9, 2012.

⁹ See FDA’s *Report on Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products* (August, 2013), FDA’s *Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data* (August, 2014), and other related information including public feedback and FDA’s current progress, at: <https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCA/FDASIA/UCM365544.pdf>.

¹⁰ 21 CFR 814.3(s) defines pediatric patients as patients who are 21 years of age or younger (that is, from birth through the twenty-first year of life, up to but not including the twenty-second birthday) at the time of the diagnosis or treatment. Available at <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=814.3>.

Contains Nonbinding Recommendations

into several age groups as described in guidance, or by developmental milestones as appropriate.^{11, 12}

(2) Race and Ethnicity

In accordance with FDA's guidance *Collection of Race and Ethnicity Data in Clinical Trials*,¹³ patients may self-identify in both an ethnic and racial category (e.g., Hispanic-White, Hispanic-Black). That guidance specified that "OMB stated that its race and ethnicity categories were not anthropologically or scientifically-based designations, but instead were categories that described the sociocultural construct of our society." The Department of Health and Human Services (HHS) chose to adopt these standardized categories for its agencies that report statistics, because the categories are relevant to assessing various health related data, including public health surveillance and research. FDA recommends the submission of applications containing clinical study data with ethnic and racial demographic data captured as two distinct categories.

More granular race-specific data may be important depending on the disease or condition (e.g., if the condition is substantially more prevalent or varied in course for Ashkenazi Jewish or Han Chinese). Additionally, FDA acknowledges that other ethnic and racial categories may be appropriate depending on the study population, (e.g., in global studies involving sites and patients outside the United States (OUS) permissible under local laws). The categories and identification method should be defined in the study protocol.

Collection and combination of data from OUS study sites may result in confounding issues of ethnicity and standard of care. OUS sites may not categorize race and ethnicity in the same manner as U.S. sites or may define certain racial or ethnicity groups differently than do U.S. sites (e.g., "Caucasian" vs "white" in European vs. U.S. data). Additionally, the standard of care at OUS sites may not be equivalent. These differences may make it difficult to combine racial and ethnic subgroup data from OUS sites. However, in some cases, differences in race and ethnicity may be controlled with the inclusion of clear definitions in the protocol which may allow for combining U.S. and OUS race- and ethnicity-specific data. The acceptability of this approach may differ across

¹¹ See FDA's guidance *Premarket Assessment of Pediatric Medical Devices*. This guidance subdivides the pediatric age group as follows:

- Newborn (neonate) – from birth to 1 month of age
- Infant – greater than 1 month to 2 years of age
- Child – greater than 2 to 12 years of age
- Adolescent – greater than 12 through 21 years of age

<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm089742.pdf>.

¹² See FDA's guidance *Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices* <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm444591.pdf>.

¹³ See FDA's guidance *Collection of Race and Ethnicity Data in Clinical Trials* <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-gen/documents/document/ucm126396.pdf>.

clinical or product areas, so we recommend you discuss any such plans for combining data with the primary review Division or Branch.

C. Why Consider Age-, Race-, and Ethnicity-Specific Differences

(1) Age

Consideration of different age populations (particularly pediatric and older patients, who are often underrepresented in clinical trials) can be important for proper characterization of a device's safety and effectiveness (or probable benefit for HDEs) in the patient population. In the 2013 FDASIA 907 Report,¹⁴ of the approved PMAs evaluated for the Report, only 40% publicly reported an age-based analysis of outcomes data. The amount of age information available was inconsistent and often not detailed enough to analyze device performance related to age. The manner in which the age descriptive statistics are presented (e.g., mean, median, standard deviation, distribution) in a submission may affect data interpretation. Proper study of device use in both older and pediatric populations is important when the device is likely to be used for these subgroups.

Older patients and pediatric patients often have co-morbidities, concomitant therapies, or development considerations that could interact with the investigational device effects and impact device performance. Older patients may have age-related covariates such as characteristics of bone density, metabolism, digestion, synovial fluid, etc. that could affect the performance of medical devices. In addition, the benefits or adverse effects of medical devices may be age dependent. A medical device might adversely affect the development of a pediatric patient but have no detrimental effect on an adult. In the case of intraocular lenses, devices are used to treat vision loss in adults and children, with the potential added benefit of improving future visual development in a young child.¹⁵ For these reasons, it is important to consistently consider the potential impact of age on device effects, and to plan studies and analyses accordingly.

FDA provides guidance on developing medical devices for pediatric population subgroups (e.g., neonates, infants, children, and adolescents).¹¹ FDA has several device-related initiatives that aim to address challenges in the pediatric subpopulation. In 2007, Congress enacted the Pediatric Medical Device Safety and Improvement Act (PMDsIA) as part of the Food and Drug

¹⁴ See FDA Report: *Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products*, issued August 2013, required under FDASIA Section 907.

<http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticAct/FDCA/SignificantAmendments/totheFDCA/FDASIA/UCM365544.pdf>.

¹⁵ Institute of Medicine (US) Committee on Clinical Research Involving Children; Field MJ, Behrman RE, editors. *Ethical Conduct of Clinical Research Involving Children*. Washington (DC): National Academies Press (US); 2004. 2, The Necessity and Challenges of Clinical Research Involving Children. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK25553/>.

Contains Nonbinding Recommendations

Administration Amendments Act of 2007 (FDAAA),¹⁶ which provides that FDA may extrapolate adult data when appropriate.

PMDSIA also requires certain medical device applications to include, if readily available, a description of any pediatric subpopulations that suffer from the disease or condition that the device is intended to treat, diagnose, or cure and the number of affected pediatric patients.¹⁷ FDA issued a guidance document outlining the implementation of this provision (FDA Guidance: *Providing Information about Pediatric Uses of Medical Devices*).¹⁸

(2) Race and Ethnicity

While the U.S. population demographic is changing, diverse representation in clinical trials remains a challenge, and inconsistent analysis and reporting contributes to a persistent lack of publicly available data on device performance in diverse ethnic and racial groups. The 2013 FDASIA 907 Report showed a distinct lack of publicly reported race- and ethnicity-specific data for medical devices.¹⁹ Only 27% of the studies reviewed contained a race- or ethnicity-specific subgroup analysis, and only 16% had public statements regarding a race- or ethnicity-specific analysis.

There are several devices where differences in effect were observed that were correlated with race and ethnicity. For example, differences in skin structure and physiology can affect response to dermatologic and topically applied products.²⁰ Mortality rates of patients on dialysis have been shown to differ across racial and ethnic groups.²¹ FDA encourages sponsors to collect race- and ethnicity-specific data according to the recommendations in the FDA Guidance *Collection of Race and Ethnicity Guidance Document*.²²

¹⁶ See PMDSIA, Title III, Public Law 110-85. Available at <http://www.gpo.gov/fdsys/pkg/PLAW-110publ85/pdf/PLAW-110publ85.pdf>.

¹⁷ Consult Pediatric uses of devices (21 U.S.C. § 360e-1). Available at <http://www.gpo.gov/fdsys/pkg/USCODE-2010-title21/html/USCODE-2010-title21-chap9-subchapV-partA-sec360e-1.htm>.

¹⁸ See FDA's guidance *Providing Information about Pediatric Uses of Medical Devices* <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM339465.pdf>.

¹⁹ See FDA's *Report on Collection, Analysis, and Availability of Demographic Subgroup Data for FDA-Approved Medical Products* (August, 2013), FDA's *Action Plan to Enhance the Collection and Availability of Demographic Subgroup Data* (August, 2014), and other related information including public feedback and FDA's current progress, at: <https://www.fda.gov/downloads/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCA/FDASIA/UCM365544.pdf>.

²⁰ Taylor, Susan C. "Skin of color: biology, structure, function, and implications for dermatologic disease." *Journal of the American Academy of Dermatology* 46.2 (2002): S41-S62.

²¹ Yan, Guofen, et al. "The relationship of age, race, and ethnicity with survival in dialysis patients." *Clinical Journal of the American Society of Nephrology* 8.6 (2013): 953-961.

²² See FDA's guidance *Collection of Race and Ethnicity Data in Clinical Trials* <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-gen/documents/document/ucm126396.pdf>.

D. Participation of Age-, Race-, and Ethnicity-Specific Subgroups in Clinical Trials

It is important that clinical trials include diverse populations that reflect the intended population, especially when clinically meaningful differences in safety, effectiveness (or probable benefit, for HDEs), or benefit-risk profile are expected across these groups. In general, to achieve an unbiased estimate of treatment effect in the general population, sponsors should develop a strategy to enroll diverse populations including relevant age, racial, and ethnic groups.

Where possible, it is also important to enroll diverse populations throughout the enrolling sites, particularly in studies where surgical or operator skill may be of key importance. If patients enrolled at one site are predominantly of one demographic subgroup, it may be possible to incorrectly attribute differences in device performance or surgical skill to demographic subgroups; this should be considered when planning and analyzing trials.

In general, study protocols should include pre-specified statistical plans for addressing these and other issues outlined in this guidance. Unplanned subgroup analyses or those with inadequate sample size are generally not considered to be adequate to support statements in the labeling regarding the safety or effectiveness of the device. However, the overall benefit-risk profile of the device will be considered.

(1) Barriers to Enrollment

Recruiting subjects to clinical studies who represent the range of age, racial, and ethnic groups consistent with the intended use population of the device may present additional challenges. There are numerous suspected reasons for low rates of participation by minority, older, and pediatric individuals in clinical trials.²³ In 2009, FDA published a Report to Congress on identified barriers to enrollment in clinical drug trials and recommendations on how to address the disproportionately low enrollment of certain populations in clinical trials, especially those trials in which these populations are highly affected by or are likely to suffer worse outcomes from the disease being evaluated.²⁴ FDA believes much of this information is relevant to medical device clinical trials as well.

The following have been identified as potential barriers to enrollment:

²³ Institute of Medicine Workshop: Strategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials. April 9, 2015. Agenda and presentations available at <http://iom.nationalacademies.org/Activities/SelectPops/HealthDisparities/2015-APR-09.aspx>.

²⁴ Report to Congress: *Food and Drug Administration Amendments Act (FDAAA) of 2007, Public Law No. 110-85 Section 901 of the Federal Food, Drug, and Cosmetic Act: Direct-to-Consumer Advertising's Ability to Communicate to Subsets of the General Population; Barriers to the Participation of Population Subsets in Clinical Drug Trials* issued September 2009. <http://www.fda.gov/downloads/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCA/SignificantAmendments/totheFDCA/FoodandDrugAdministrationAmendmentsActof2007/FDAAImplementationChart/UCM214303.pdf>.

Contains Nonbinding Recommendations

- lack of understanding about the main obstacles to participation of different age, racial, and ethnic groups in clinical research;
- inclusion/exclusion criteria that unintentionally exclude different age, racial, or ethnic groups (e.g., creatinine levels for African-Americans);²⁵
- lack of understanding about differences in disease etiology and pathophysiology may lead to under-diagnosis and under-referral of specific demographic subgroups;
- patient concerns with being assigned to treatment versus control group, randomization, possible side effects, privacy, and historical mistrust of clinical trial ethics;
- language, cultural, and health literacy differences between investigators and patients;
- investigator and sponsor avoidance of specific age, racial, or ethnic groups of patients due to the perception that it is more difficult and potentially more expensive to recruit and maintain participation;
- lack of diverse investigators in studies who may have access to a more diverse patient pool to recruit subjects;
- pressure on investigators to quickly enroll patients regardless of demographic characteristics;
- perceived ethical concerns among investigators regarding enrollment of certain demographic groups in clinical trials;
- trial logistics (e.g., transportation, childcare) may disproportionately affect specific age, racial and ethnic groups' ability to complete study follow-up visits;
- disproportionate drop out and lost-to-follow-up rates;^{26, 27} and
- type or location of study sites may limit participation of specific age, racial, or ethnic groups.

(2) Enrollment Resources

Where ongoing enrollment data demonstrate an underrepresentation of certain subgroups enrolling in the study, sponsors are encouraged to investigate the reason(s) for lack of enrollment and consider the approaches in Section IV to enhance enrollment. It may be informative to evaluate whether the demographic

²⁵ (removed)

²⁶ Institute of Medicine Workshop: Strategies for Ensuring Diversity, Inclusion, and Meaningful Participation in Clinical Trials, April 9, 2015. Agenda and presentations available at <http://iom.nationalacademies.org/Activities/SelectPops/HealthDisparities/2015-APR-09.aspx>.

²⁷ Wendler, David, et al. "Are racial and ethnic minorities less willing to participate in health research?" *PLoS medicine* 3.2 (2006): 201.

Contains Nonbinding Recommendations

distribution varies at different key time points (e.g., at screening, after evaluation of study inclusion/exclusion criteria, after consent, and at various follow-up time points). Information regarding changes in demographic distribution at key time points in study screening, enrollment, and follow-up can provide insight into root causes of lower enrollment rates in these groups. This analysis may help identify ways to substantially lower barriers to enrollment of age-, race-, and ethnicity-specific subgroups that have been shown to improve enrollment rates and study retention rates in other subgroups of study subjects, (e.g., flexibility in follow-up visit scheduling, with consideration of child care or elder care services during appointments).²⁶ Changes to a study protocol and informed consent may be made based on demographic distribution information with appropriate notification to and approval from an Institutional Review Board (IRB) and the FDA, where necessary.

Sponsors may also wish to consider resources developed by the National Institutes of Health (NIH),^{28, 29, 30, 31} discussion with academic and contract research organizations, and practices of high-enrolling clinical study sites in determining practices best suited to achieve appropriate enrollment of demographic groups, and to provide investigator training about these techniques. Some specific examples of strategies to increase inclusion of diverse study populations are discussed in Section IV below.

IV. Recommendations for Achieving Appropriate Enrollment

Historically, many medical device clinical studies have not enrolled proportions of age, racial, and ethnic subgroups that reflect the underlying disease distribution in the affected population. This can be problematic because the ability to detect differences in response to treatment is markedly diminished if there is no or limited clinical experience with the product in the subgroup of interest. This has contributed to a substantial lack of available data regarding the risks and benefits of medical device use in certain age, racial, and ethnic subgroups. Thus, it is important that clinical trials include diverse populations that reflect the intended population whenever possible and appropriate.

²⁸ NIH Office of Research on Women's Health has a number of publications available which provide advice on inclusion criteria, an overview of key elements in recruitment and retention, and a number of practical applications for conducting human subjects research, including ethical considerations. <http://orwh.od.nih.gov/research/inclusion/index.asp>.

²⁹ The National Institute of Mental Health developed a resource document ("Points to Consider about Recruitment and Retention While Preparing a Clinical Research Study", June 2005), which outlines common issues that can impact clinical recruitment and retention, and strategies to address these issues. http://www.nimh.nih.gov/funding/grant-writing-and-application-process/recruitment-points-to-consider-6-1-05_34848.pdf.

³⁰ The National Cancer Institute developed an online resource designed for practicing professionals to support clinical trial accrual needs. The Web site is a repository for literature and other resources and serves as a 'community of practice' to encourage dialog and discussion. <https://accrualnet.cancer.gov>.

³¹ The National Institute on Minority Health and Health Disparities is active in the area of minority recruitment to trials. <http://nimhd.nih.gov>.

Contains Nonbinding Recommendations

In general, to achieve an unbiased estimate of treatment effect in the general population, sponsors should ideally plan to enroll representative proportions of age-, race-, and ethnicity-specific subgroups that are consistent with the intended use population of the device, or justify in the investigational plan how the enrollment criteria will provide reasonable representation of the intended or affected population. A simple justification may suffice in cases where factors other than age, race, and ethnicity are primarily of interest. For example, anatomical size may be the primary factor for a device indicated for patients who demonstrate a particular anatomical size, even though anatomical size may vary according to age, race, or ethnicity.

In cases where known disease science or prior clinical study results suggest a clinically meaningful difference in benefits or risks in one or more age, racial, or ethnic subgroups, sponsors should aim to enroll sufficient numbers of that demographic subgroup(s) to support robust analysis (i.e., a sample size sufficient for age, race, or ethnicity-specific claims or outcomes).

To overcome some of the barriers to adequate representative enrollment, FDA recommends the following considerations as sponsors proceed with their device development plans.

A. Consideration of Potential Age-, Race-, and Ethnicity-Specific Differences

To understand potential age-, race-, and ethnicity-specific differences that may be relevant to the clinical evaluation of your device, we recommend that, for the disease or condition your device is intended to treat or diagnose, you identify and consider:

- Age-, race-, and ethnicity-specific prevalence, if known;
- Age-, race-, and ethnicity-specific diagnosis and treatment patterns, if known;
- proportions of age-, race-, and ethnicity-specific subgroups included in past studies for the target indication, if known; and
- any known clinically meaningful age-, race-, and ethnicity-specific differences in outcomes related to either safety or effectiveness (or probable benefit for HDEs).

If information demonstrating age-, race-, and ethnicity-specific differences in these areas is available, you should consider this information when designing your study protocol and include a discussion about these considerations in your submission documents as described in the following sections. FDA recognizes that such information is limited in some device development programs (e.g., those based on testing of de-identified non-annotated specimens).

(1) Study Design, Early Enrollment Stage

You should include the information described above as part of your investigational plan (see 21 CFR 812.25(c)) for investigational device exemption (IDE) studies. We also recommend that you summarize this information in your study protocol and investigator training materials to explain the importance of enrolling appropriate proportions of age, racial, and ethnic subgroups.

Contains Nonbinding Recommendations

For studies that are already enrolling under an approved (or conditionally approved) IDE, where there is inadequate enrollment of age, racial, and ethnic subgroups, you should discuss with FDA an appropriate path to communicate this new information to investigators and how to use it without introducing bias to the study.

(2) Premarket Submission Stage

You should include this information as part of your marketing application in sections containing results of clinical investigations. A summary of any known clinically meaningful age-, race-, and ethnicity-specific differences in disease course, outcomes, or benefit-risk profile should also be included in your 510(k) Summary and in your labeling (see Section VI below for more details).

FDA staff should include this information in the PMA Summary of Safety and Effectiveness, HDE Summary of Safety and Probable Benefit, and De Novo decision summaries, which will be made publicly available on FDA's website.

(3) Postmarket Submission Stage

You should include this information in interim reports and in the results section of your final report for mandated postmarket study(ies). Where available background information or clinical study results suggest there are clinically meaningful age-, race-, and/or ethnicity-specific differences in disease course, outcomes, or benefit-risk profile, you should also submit revised labeling to include this information. FDA encourages the use of postmarket data to modify labeling to support additional information regarding device safety or effectiveness and/or clarify how the device should be used.

B. Planning for Diverse Study Recruitment

The approaches described below are aimed at increasing enrollment of age, racial, and ethnic subgroups in your study, as appropriate, with a goal of participation consistent with the intended use population of the device. In general, when clinically meaningful differences in treatment effect are anticipated across age, racial, or ethnic groups, these effects should be considered during study planning. Some of these methods may also be adapted to increase enrollment of other typically underrepresented groups. These methods should be considered in addition to factors highlighted in the FDA guidance on *Design Considerations for Pivotal Clinical Investigations for Medical Devices*.³²

³² See FDA's guidance *Design Considerations for Pivotal Clinical Investigations for Medical Devices*.
<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM373766.pdf>.

(1) Study Design, Early Enrollment Stage

You should develop and describe your plan to prospectively include appropriate demographic subgroups in your study based on the contextual information provided in Section IV.A. (i.e., consistent with the intended use population, including age, racial, and ethnic prevalence of the disease or condition which your device is intended to treat or diagnose, if known). To enhance enrollment of relevant age, racial, and ethnic subgroups, the approaches described below may be considered, with appropriate caution to avoid introducing bias or jeopardizing data validity.

- a. Include a wide variety of investigational sites where recruitment of age, racial, and ethnic subgroups can be more easily facilitated (e.g., community clinics, nursing homes, pediatric hospitals, minority healthcare provider groups, urban hospitals).
- b. Consider alternative communication strategies for study recruitment, informed consent documents, and patient materials (e.g., involvement of community-based organizations and places of worship, patient reading materials in multiple languages with appropriate cultural references, patient reading materials appropriate for low-literacy populations, accommodations for the visual- and hearing-impaired, patient reading materials in electronic versions, use of social media).
- c. If age-, race-, and ethnicity-specific subgroups are expected to benefit, or benefit differentially, from your device but may not meet certain study enrollment criteria, consider revising the enrollment criteria, when appropriate, or consider enrolling registries or parallel cohorts for collecting data on device use in particular age-, race-, and ethnicity-specific subgroups (e.g., a pediatric registry).
- d. Consider including provisions to encourage diverse enrollment of relevant age, racial, and ethnic subgroups consistent with the intended use population.
- e. Consider investigating reasons for under-enrollment or non-enrollment of age, racial, and ethnic subgroups or other key demographic groups (e.g., consider periodically evaluating screening logs for all patients who are screened but not ultimately enrolled in studies to identify and address root cause barriers to diverse enrollment).³³
- f. Consider planning focused efforts to enroll age, racial, and ethnic subgroups under a continued access study based on prior information or information

³³ Wendler, David, et al. "Are racial and ethnic minorities less willing to participate in health research?" *PLoS medicine* 3.2 (2006): 201.

Contains Nonbinding Recommendations

collected in a study.³⁴

- g. Consider factors that generally increase recruitment and retention such as utilizing community or local health care practitioners, minority health professional organizations, and patient advocacy groups for recruiting or referring patients; compensation for expenses (e.g., for transportation costs); and maintaining communication with subjects (e.g., sending a newsletter to subjects to maintain interest, using social media).
- h. Consider flexibility in follow-up visit scheduling with provision of child care or elder care services during appointments or to allow various opportunities that match subjects' schedules, which may include evenings and weekends.
- i. For *in vitro* diagnostic tests and diagnostic devices, consider including samples from each age, racial, and ethnic subgroup at the cutoff selection and validation stages. For *in vitro* diagnostic devices in which a reference interval is provided, and for which differences are expected in certain demographic subgroups (e.g., B-Type Natriuretic Peptide (BNP) diagnostic test with age-specific clinical cutoffs), also consider collecting data by demographic subgroup when appropriate.

(2) Premarket Submission Stage

In your marketing submission, you should discuss study results (related to safety and/or effectiveness, or probable benefit for HDEs) and describe how any known, clinically meaningful age-, race-, and ethnicity-specific differences across subgroups may contribute to differences in benefit-risk profile in certain subpopulations.

When determining whether additional data collection is needed to address a clinically important question before the device is marketed, consideration should be given to whether market approval/clearance is supported for the general population, with postmarket studies to gain further information regarding any observed age-, race-, or ethnicity-specific subgroup differences, or whether existing results support market approval/clearance in a specific age-, race-, or ethnicity-specific subgroup, but additional premarket data collection would be needed to generalize effects to a broader intended use population.

If additional data is needed before the device is approved or cleared, FDA may recommend that you consider including provisions to encourage enrollment of diverse age, racial, or ethnic subgroups (e.g., modification of enrollment criteria to study outcomes in a specific subpopulation). In such cases, we recommend

³⁴ See FDA's *Guidance on IDE Policies and Procedures*
<http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080202.htm>.

Contains Nonbinding Recommendations

you discuss your plans to limit introducing bias or jeopardizing data validity with FDA.

(3) Postmarket Submission Stage

We recommend you consider whether outstanding questions warrant postmarket evaluation in a specific age, racial, or ethnic subgroup. For example, postmarket data collection may be warranted if premarket clinical studies reveal signals of potentially clinically meaningful outcome differences in age, racial, or ethnic subgroups, or if there are known subgroup differences in the underlying disease or the response to concomitant treatment or therapies that may affect safety or effectiveness (or probable benefit for HDEs). In such instances, FDA may determine that additional study of a particular age, racial, or ethnic subgroup is warranted in the postmarket setting.

You should develop and describe your plan to collect postmarket data on appropriate demographic subgroups in any mandated postmarket study(ies) based on outstanding questions described above, and/or based on the contextual information provided per Section IV.A. (e.g., consistent with the intended use population, including age, racial, or ethnic prevalence of the disease or condition that your device is intended to treat or diagnose, if known).

To enhance enrollment of age, racial, or ethnic subgroups, we recommend that you consider the approaches specified in Section IV.B.1.

C. Considerations for Study Follow-up Visits

We also recommend that sponsors and clinical study investigators consider the approaches described below, which can help avoid or minimize loss-to-follow-up of subjects (regardless of age, racial, or ethnic subgroup).³⁵ While proper study conduct and follow-up are concerns for all patients, regardless of age, race, or ethnicity, concerns about disproportionate dropout and loss to follow-up are potential barriers to diverse study representation of minorities and older patients. The following considerations represent good clinical study principles that may improve diverse participation throughout the duration of the study. We encourage sponsors and clinical study investigators to consider these where appropriate.

Sponsors should consider:

- a. Developing a follow-up plan that details follow-up goals, frequency of scheduled follow-up visits, proxy contact information, and actions to be taken when a patient misses a follow-up visit.

³⁵ National Research Council. 2010. *The Prevention and Treatment of Missing Data in Clinical Trials*. Washington, DC: The National Academies Press.

Contains Nonbinding Recommendations

- b. Demonstrating continued interest in the subjects (e.g., sending a newsletter to subjects to maintain interest).
- c. Monitoring follow-up rates closely so that follow-up problems can be identified and addressed as soon as possible.
- d. Reporting subject accountability data as part of the study report.

Investigators should consider:

- a. Participating in cultural competency training prior to study recruitment.
- b. During informed consent and thereafter, counseling subjects about the importance of returning to follow-up.
- c. Reminding subjects of upcoming follow-up visits.
- d. Attempting to locate subjects who miss scheduled clinic visits and encouraging them to return.
- e. Obtaining proxy contact information to use when unable to contact a study subject.
- f. Asking subjects who withdraw during the study to provide the reason for withdrawal and whether the investigator may contact them once more at the end of the study follow-up to assess their experience with the device.
- g. Providing close follow-up with subjects (e.g., telephone follow-up after surgery, particularly if the device is implantable).

V. Considering Age, Race, and Ethnicity in Study Design, Analysis, and Interpretation of Study Results

Intrinsic and extrinsic biological differences across age, racial, and ethnic groups (e.g. gonad development, skin texture, skin color, hormone levels, metabolism, degenerative disease, bone density, cell receptors, genomic variations) exist that may influence the safety and effectiveness (or probable benefit for HDEs) of a device. For example, ionizing radiation exposure to pediatric patients from medical imaging procedures is of a different concern than that for adults because pediatric patients are more radiosensitive (i.e., the cancer risk per unit dose of ionizing radiation is higher).³⁶ Additionally, age, race, and ethnicity may play a role in an individual's interaction with his/her environment, which in turn could affect an individual's health. For example, intermittent exposures to intense UV radiation leading to sunburns (e.g., through the use of tanning beds), especially in childhood and teen years, increase the risk of melanoma.³⁷

Due to the potential impact on safety and effectiveness (or probable benefit for HDEs), unless the investigational device is intended for use in only one age, racial, or ethnic group (e.g., neonatal devices), it is important that the variation in potential response or outcomes across age,

³⁶ See FDA's website on *Pediatric X-Ray Imaging*, available at <http://www.fda.gov/Radiation-EmittingProducts/RadiationEmittingProductsandProcedures/MedicalImaging/ucm298899.htm>.

³⁷ See FDA's website on *Indoor Tanning: The Risks of Ultraviolet Rays*, available at <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm186687.htm>.

Contains Nonbinding Recommendations

racial, and ethnic groups be accounted for both in study design and in analysis of results, as appropriate.

Other patient characteristics (e.g., body size, diet, bone density, Fitzpatrick Scale Skin Type) that may be correlated with age, racial, or ethnic differences might sometimes explain apparent differences in clinical outcomes. If differences between evaluated subgroups are observed in the clinical study, FDA recommends that a sponsor investigate whether other patient characteristics may explain the observed differences. This will help users identify characteristics that can inform decision making for individual use.

When using real-world evidence or real-world data collected from sources outside of traditional clinical trials, it is important to assess the intended use population and how well the representation of the intended use population is collected in the real-world evidence source.

As discussed in Section III.B., demographic data can be collected and categorized in a variety of ways. The categorization scheme you choose may impact your analysis (e.g., depending on whether age is treated as a categorical or continuous variable).

A. Assessing Heterogeneity Across Age, Racial, and Ethnic Subgroups

There may be substantial differences in device safety and effectiveness (or probable benefit for HDEs) across age, racial, and ethnic subgroups. Sponsors should investigate heterogeneity across these demographic subgroups of clinical interest, especially for primary safety and effectiveness endpoints (or probable benefit for HDEs).

Heterogeneity here refers to a variation in outcome across subgroups. Statistical hypothesis tests can be performed to detect heterogeneity, and methods of statistical inference for estimating its magnitude are also available. As statistical tests, hypothesis test significance levels should be pre-specified in an investigational plan for premarket or postmarket studies. Note, however, that the power of such tests may be unspecified.

In some cases the test for treatment by subgroup interaction (or heterogeneity in general) may have adequate power to detect only a very large interaction (or heterogeneity), but may not detect a smaller yet potentially clinically meaningful interaction (or heterogeneity). Tests for treatment by subgroup interaction may lack a significant interaction based on an interaction p-value. If an interaction is detected, sponsors should evaluate which subgroups are the same or different. Such situations may arise when the number of patients in one or several of the age, racial, or ethnic groups is very small. Alternatively, observed heterogeneity across specific subgroups could be attributable to chance associated with small sample sizes. Thus, the interpretation of clinical meaningfulness may be premature in those cases. Additionally, sample sizes in subgroups may not be large enough to detect clinically meaningful differences in device safety or effectiveness (or probable benefit for HDEs). Consultation with FDA is recommended in these cases to ensure appropriate interpretation of analysis results.

Contains Nonbinding Recommendations

For additional discussion of statistical concepts for assessing heterogeneity, please see Section V.A of the *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* Guidance, hereafter referred to as the Sex-Specific Guidance.³⁸

The recommendations in the following sections of the Sex-Specific Guidance are applicable to the consideration of age, racial, and ethnic subgroups through the stages of product development and evaluation.

(1) Study Design, Early Enrollment Stage

- When appropriate, the Statistical Analysis Plan (SAP)³⁹ in the study protocol should include pre-specified plans for addressing the subgroup analysis issues described in the sections below.
- In general, to achieve an unbiased estimate of treatment effect in the general population, sponsors should develop a strategy to enroll diverse populations including relevant age, racial, and ethnic groups.
- If differences are anticipated, sponsors should make an effort to identify in advance any key covariates that might explain possible differences across subgroups, plan to collect data on these covariates, and pre-specify a modeling approach to investigate the extent to which these covariates can explain the observed differences.
- Sponsors should consider whether clinical outcome measurements will or could differ across age-, race-, or ethnicity-specific subgroups. For example, keloid formation following wrinkle filler application may differ between pigmented and non-pigmented skin, a characteristic that varies with race and/or ethnic background. Clinical measurements and endpoints in such a trial may differ across self-reported racial or ethnic subgroups, and this information should be captured accordingly.

(2) Premarket Submission Stage

- In general, sponsors should submit descriptive statistics for outcomes of interest by demographic subgroup as detailed in Section C below. After overall effectiveness (or probable benefit for HDEs) and safety have been investigated, pre-planned outcome analysis by age, race, and ethnicity for primary endpoints for both safety and effectiveness (or probable benefit for HDEs) should be conducted.

³⁸ See FDA's guidance *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf>.

³⁹ See FDA's guidance *Design Considerations for Pivotal Clinical Investigations for Medical Devices*. <http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM373766.pdf>.

Contains Nonbinding Recommendations

- When exploring age-, race-, or ethnicity-specific differences during analysis of premarket study data, we recommend you address the issue of confounding by using multivariable analyses adjusted for patient characteristics that may confound the relationship between the analyzed subgroup and study outcomes (e.g., body size, diabetes).
- If any clinically meaningful differences are suspected, either based on pre-specified or exploratory analyses, sponsors should discuss with FDA to determine whether additional data are needed to address any remaining subgroup-specific questions of safety or effectiveness (or probable benefit for HDEs).

(3) Postmarket Submission Stage

- For any mandated postmarket study(ies) involving continuing data collection on PMA cohort patients for the evaluation of longer-term performance, we recommend that you conduct the analyses described in Section C below for all follow-up time points.
- For any mandated postmarket study(ies) involving newly enrolled patients, you should include the analyses described in Section C below as part of a pre-specified SAP in your protocol. Furthermore, if results from demographic subgroup analyses of premarket data suggest there may be a clinically meaningful difference in outcomes, you should consult with FDA as to whether these differences should also be incorporated into the study design and hypothesis for your postmarket study.
- When you are exploring age-, race-, or ethnicity-specific differences during analysis of data from any mandated postmarket study(ies), we recommend you address the issue of confounding. This can be addressed by using multivariable analyses adjusted for patient characteristics that may confound the relationship between the analyzed subgroup and study outcomes (e.g., body size, diabetes).

B. Designing Studies: Recommendations for Subgroup Specific Statistical Elements

FDA recommends sponsors consider the subgroup-specific statistical elements described in detail in Section V.B. of the Sex-Specific Guidance,⁴⁰ which are applicable to the demographic subgroups outlined in this guidance. Please refer to Figure 1 in the Appendix of this guidance for a summary of these recommendations. The following specific topics apply to clinical trials for subgroup-specific outcome analyses:

⁴⁰ See FDA's guidance *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf>.

(1) Recommendations When Subgroup Differences are Anticipated

When differences in treatment effect are clearly anticipated across age, racial, or ethnic groups based on biological basis and/or previous clinical experience, it is important to consider proper clinical study design, sufficient enrollment of subgroups to allow meaningful analysis, and controlling of study-wise Type 1 error for overall and subgroup-specific hypothesis testing if appropriate.⁴¹

(2) Recommendations for Pre-specifying Assessment of Heterogeneity

It is important that the SAP include a strategy for assessing heterogeneity across relevant demographic subgroups, and FDA recommends such an assessment as an integral part of interpreting study results for every submission. In particular, the heterogeneity assessment can serve as the basis for combining data conditions for studies with pre-specified success criteria expressed in terms of combining data across subgroups. Such combining data conditions bear some resemblance to those commonly used for determining whether data can appropriately be combined for analysis across different clinical sites. Combining data conditions may be specified as statistical hypothesis tests, which, for studies involving the comparison of two treatments, would typically be tests of treatment by subgroup interaction. The interaction tests should ideally be able to detect interaction of relevant magnitude measured on pertinent parameters with a reasonably high probability, and this goal should guide the choice of appropriate significance level.

Additionally, adaptive study design strategies to pre-specify subgroups of interest for interim analysis and potential population enrichment for success should be preplanned and specified in the SAP prior to the start of the study.⁴²

(3) Additional Design Recommendations for Comparative and One-arm Studies

Application of certain study design recommendations may prompt a different approach depending on whether studies are comparative or single-arm. Please refer to Section V.B. of the Sex-Specific Guidance⁴³ for details.

⁴¹ See FDA's guidance *Design Considerations for Pivotal Clinical Investigations for Medical Devices*.

<http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM373766.pdf>.

⁴² See FDA's guidance *Adaptive Designs for Medical Device Clinical Studies*

<http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446729.pdf>.

⁴³ See FDA's guidance *Evaluation of Sex-Specific Data in Medical Device Clinical Studies*

<http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf>.

C. Completed Studies: Recommendations for Analysis of Subgroup-Specific Data

Please refer to the Appendix of this guidance for flowchart diagrams summarizing the recommendations for the analysis of subgroup-specific data in completed one-arm (Figure 2) and comparative studies (Figure 3). For detailed recommendations on the analysis in completed one-arm or comparative studies, please see the Sex-Specific Guidance Section V.C.⁴⁴

In general, sponsors should submit descriptive statistics for enrolled patients and outcomes of interest, including the estimate of variance or standard deviation (as applicable) by age, racial, and ethnic groups. At the primary follow-up time-point, regardless of the potentially limited statistical power of these specific subgroup analyses, data should be examined for clinically meaningful age-, race-, and ethnicity-specific differences in each of the following:

- primary effectiveness (or probable benefit for HDEs) endpoint(s);
- primary safety endpoint(s); and
- key secondary endpoints.

It is important to carry out all analyses set forth in the SAP. FDA expects sponsors to plan for and conduct analyses to evaluate heterogeneity by demographic subgroups, including treatment by subgroup interaction when applicable, as described in previous sections.

Unplanned subgroup analyses or those with inadequate sample size are generally not considered to be adequate to support statements in the labeling regarding the safety or effectiveness of the device. However, the overall benefit-risk profile of the device will be considered.

- If there is evidence of heterogeneity, it is important to describe its nature and assess the clinical importance of the differences. In some cases, the effect could be statistically significant, but not clinically meaningful, or clinically meaningful but not statistically significant. In these cases, discussion with FDA is advised.
- If a clinically meaningful and/or statistically significant difference is observed across certain subgroups (e.g., age less than 65 years old, between 65 and 75 years old, and over 75 years old), it is important to investigate further about the cause and discuss with FDA. Also, it is suggested to consider whether the observed heterogeneity could be mainly explained by other covariates, which are highly correlated with that subgroup and the treatment effect (e.g., confounders or effect modifiers).

⁴⁴ See FDA's guidance *Evaluation of Sex-Specific Data in Medical Device Clinical Studies* <http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm283707.pdf>.

Contains Nonbinding Recommendations

If a difference remains clinically meaningful and/or statistically significant after consideration of other covariates, data may not be combined across subgroups. In this case, discussion with FDA is recommended. Sponsors should describe how any clinically meaningful differences across subgroups may contribute to differences in the benefit-risk profile in certain subpopulations.

D. Interpretation of Age-, Race-, and Ethnicity-Specific Data

- If any clinically meaningful demographic subgroup differences are found, based either on pre-specified or exploratory analyses, you should discuss with FDA whether additional data are needed to address any remaining subgroup-specific questions. Hypotheses for exploratory analyses should be consistent with the literature of the natural history of the disease and its prevalence in subgroups or be consistent with the known pathophysiology. You should describe how any clinically meaningful differences across subgroups may contribute to differences in benefit-risk profile in certain subpopulations.
- If results of your analysis suggest that there is insufficient data to assess whether age, race, or ethnicity is associated with clinically meaningful differences in outcome, FDA may determine that clinical data from additional subjects in one or several of demographic subgroups may be needed pre- or postmarket to address potential age-, race-, or ethnicity-specific questions related to safety or effectiveness (or probable benefit for HDEs) in any or all of those subgroups.
- Although expected to be rare, in cases where clinically meaningful differences among the age, racial, or ethnic groups are observed in safety or effectiveness (or probable benefit for HDEs), FDA may request additional confirmatory studies, implement specific pre- or post-approval study conditions, and/or recommend modifications to the design of subsequent studies. FDA will consider such requests in the context of a benefit-risk framework. Sponsors should describe how any observed clinically meaningful differences across subgroups may affect overall benefit-risk profile in certain subpopulations.
- There are limitations to interpreting clinically meaningful differences in small data sets or in larger studies in which certain subgroups are underrepresented. Mean differences could exist among demographic subgroups due to small sample sizes, and interpretation about whether they are clinically meaningful may be premature in many cases. Alternatively, sample sizes may not be large enough to detect clinically meaningful differences in device safety or effectiveness (or probable benefit for HDEs). Consultation with FDA is recommended in these cases.

VI. Recommendations for Submitting Age-, Race-, and Ethnicity-Specific Data in Submissions to the Agency and Reporting in Public Documents

Contains Nonbinding Recommendations

Confidential submissions to FDA contain detailed analyses of clinical study data, which may include a variety of age, racial, and ethnic subgroup analyses. However, public documents, including labeling and FDA summaries of review (e.g., Summary of Safety and Effectiveness Data, De Novo Decision Summaries, 510(k) Summaries) for medical devices approved or cleared in the past are inconsistent with regard to the degree of information reported on device performance in demographic subgroups. The term “submit” refers to information submitted to the FDA for analysis, whereas the term “report” refers to information that should be included in publicly available documents (i.e., labeling,⁴⁵ FDA review summaries). Although sponsors may be most interested in the generalizability of the findings, individual patients and their medical providers may benefit from more data regarding effectiveness (or probable benefit for HDEs) and potential adverse events associated with device use in a particular demographic subgroup.

Please refer to Figure 4 in the Appendix for a flowchart summary of the below recommendations.

A. Enrollment Demographics, Baseline Characteristics & Co-Morbidities

The strength of the conclusions of your clinical study(ies) with respect to device performance in age, racial, and ethnic subgroups is linked to the number of individuals in the age, racial, and ethnic subgroups in your study(ies). FDA recommends that you submit and publicly report the number and proportion of subjects by age, racial, and ethnic groups who were treated or diagnosed with your device as part of a clinical study as follows:

- You should submit and publicly report study demographics in terms of proportion enrolled and completed by subgroup. You should discuss whether the proportions enrolled are consistent with the age, racial, and ethnic prevalence of disease, if known. If proportions enrolled are substantially different than prevalence of disease by age, race, and ethnicity, if known, you should discuss generalizability of study findings to the demographic subgroups. For studies with multiple cohorts, you should submit and publicly report enrollment proportions for each age, racial, and ethnic subgroup in each cohort.
- If co-morbidities and/or other baseline characteristics are collected, you should analyze and submit these by demographic subgroup as well as overall.
- If loss to follow-up disproportionately affects a particular subgroup (e.g., greater loss of older patients compared to younger patients), you should provide a discussion of differences across subgroups at different time points for the overall study sample and for each study arm. Different patterns in missing data may introduce bias in the study conclusions.

⁴⁵ See FDA’s *Guidance on Medical Device Patient Labeling*
<http://www.fda.gov/downloads/MedicalDevices/MedicalDeviceRegulationandGuidance/GuidanceDocuments/ucm070801.pdf>.

Contains Nonbinding Recommendations

When publicly reporting, you may adapt the example language below or use similar language that incorporates the contents described above. Conclusions should only be based on factual data and not be assumptions or inferences based on non-significant trends or exploratory analyses.

Example Language:

African-American women represented [%] of the total patients enrolled in the overall study. The prevalence of [uterine fibroids] among African-American women in the U.S. is [%], according to [source]. Among subjects in the treatment group, m1/n1 (p1%) were African-American women, and m2/n2 (p2%) of subjects in the control group were African-American women.

Pediatric patients were more likely to have [disease or diagnosis] compared to adults (p1% vs. p2%).

Additionally, we recommend that you include this type of information in any applicable tables and charts.

(1) IDE Stage

You should submit demographic information outlined above as part of your IDE annual progress reports.

(2) Premarket Submission Stage

If your 510(k) submission includes clinical data, you should submit baseline demographic information outlined above as part of your submission in sections containing results of clinical investigations, including the labeling. You should also report a summary of this information in your 510(k) Summary, which will be made publicly available on FDA's website upon clearance.

FDA staff should include this information in the PMA Summary of Safety and Effectiveness, HDE Summary of Safety and Probable Benefit, and De Novo decision summaries, which will be made publicly available on FDA's website.

(3) Postmarket Submission Stage

You should submit the demographic information outlined above in interim reports and in the final report for any mandated postmarket study(ies).

Contains Nonbinding Recommendations

FDA staff should include this information in mandated study summaries, which are made publicly available on FDA's website, when appropriate.

B. Age-, Race-, and Ethnicity-Specific Outcomes (Safety or Effectiveness, or Probable Benefit for HDEs)

Outcomes analyses by demographic subgroup should be reported in the labeling and review summaries, as outlined below. Covariates that might explain possible outcome differences by age, race, and ethnicity should be described.

- If outcome differences by age, race, and ethnicity are statistically significant and clinically meaningful, you should report the results of the outcome analyses. You should also describe how such differences across subgroups affect the benefit-risk profile in certain subpopulations, as applicable.
- If results of these analyses suggest an age-, race-, and/or ethnicity-specific difference in an endpoint or event that is clinically meaningful, but not statistically significant, you should report the findings descriptively.
- If results of these analyses suggest no age-, race-, and/or ethnicity-specific differences in outcomes, you should report which analyses were conducted and that no clinically meaningful differences were found to be relevant.

When publicly reporting, you may choose to adapt the example language and graph below, or you may use similar language, tables, and charts that incorporate the contents described above. The example below is one option. Alternatively, you may choose to illustrate performance separately by race and then by ethnicity, as the subgroups will be larger, improving the ability to ascertain subgroup effects.



It should also be noted that where there are many subgroups with small sample size, one may observe considerable variability in treatment effect due to random chance. Any such variability should be interpreted with caution.

Example Language & Graph:

The study data suggests a trend that patients of [age] years of age have a higher [study outcome] in comparison to patients of [age] years of age, but these differences were not found statistically significant by [x] statistical analysis.

Tables or Forest plots showing outcomes by demographic subgroups are potential options for reporting outcomes.

Contains Nonbinding Recommendations



Sample forest plots of hazard ratios by race- and ethnicity-specific subgroups

Per FDA guidance, FDA recommends the two-question format to collect data about race and ethnicity. These sample plots were generated for illustrative purposes and do not reflect actual

Contains Nonbinding Recommendations

clinical data. If the number of subjects is very small, a confidence interval may be too wide to be meaningful.⁴⁶

(1) Premarket Submission Stage

There may be two objectives for pre-specified age-, race-, and ethnicity-specific subgroup analysis: (1) for subgroup-specific labeling information and (2) for reporting purposes as recommended for all submissions. When submitting or publicly reporting results of *pre-specified* age-, race-, and ethnicity-specific subgroup analyses to support subgroup-specific labeling, we recommend the following:

- Clearly state which analyses were conducted.
- Specify statistical methods used to assess for heterogeneity of treatment differences by age, race, and ethnicity (as described above).
- You may include inferential statistics, including p-values and/or confidence intervals, if there is pre-specified statistical hypothesis testing for a subgroup with multiplicity adjustment. To provide appropriate context, describe prior scientific evidence suggesting that clinically meaningful differences by subgroup are expected, or describe statistical limitations of analyses.

Sponsors should consider the following when submitting or publicly reporting results of exploratory age-, race-, and ethnicity-specific subgroup analyses:

- Clearly state which analyses were conducted.
- Specify statistical methods used to assess for heterogeneity of treatment differences by age, race, and ethnicity (as described above).
- Use descriptive statistics only (mean, standard deviation, etc.).

If clinically meaningful age-, race-, and ethnicity-specific differences in safety or effectiveness (or probable benefit for HDEs) are observed, or if there are potential differences that might require follow-up studies, you should include in publicly reported labeling and review summaries a discussion on whether or how this affects the overall benefit-risk profile for different subgroups.

(2) Postmarket Submission Stage

When presenting results of age, racial, and ethnic subgroup analyses of any mandated postmarket study(ies), the recommendations above also apply.

⁴⁶ See FDA's guidance *Collection of Race and Ethnicity Data in Clinical Trials* <http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-gen/documents/document/ucm126396.pdf>.

Contains Nonbinding Recommendations

If a clinically meaningful signal is detected in your final analysis, FDA may recommend changes to your approved labeling documents.

Appendix 1 – Decision Framework

We encourage the use of existing scientific data (e.g. recent previous studies, disease natural history studies) to determine whether there is a hypothesis for a clinically meaningful demographic subgroup-specific difference for your device. When there is a hypothesis for a clinically meaningful difference, the following decision trees provide a framework in deciding when various age-, race-, or ethnicity-specific statistical recommendations apply for different clinical study designs. Sponsors should also describe how any clinically meaningful differences across subgroups may contribute to differences in benefit-risk profile in certain subpopulations.

Figures 1-4 include flowchart summaries of the recommendations provided in Sections V and VI. Please refer back to these sections for a detailed explanation of the recommendations.

Figure 1: Recommendations for Demographic Subgroup-Specific Statistical Study Design





Figure 2: Recommendations for Demographic Subgroup-Specific Statistical Analysis for One-Arm Studies (Objective Performance Criterion, Performance Goal, Observational Study)




*Unplanned subgroup analyses are generally not considered to be adequate to support statements in the labeling regarding the safety or effectiveness of the device if overall treatment effect is not statistically significant and clinically meaningful.

**Provide justification for combining data across subgroups, if applicable.

Note: In some cases, the subgroup-specific difference can be 1) statistically significant but not clinically meaningful or 2) clinically meaningful but not statistically significant. In these cases, discussion with FDA is advised.

Figure 3: Recommendations for Demographic Subgroup-Specific Statistical Analysis for Comparative Studies




*Unplanned subgroup analyses are generally not considered to be adequate to support statements in the labeling regarding the safety or effectiveness of the device if overall treatment effect is not statistically significant and clinically meaningful.

**Provide justification for combining data across subgroups, if applicable.

Note: In some cases, the subgroup-specific difference can be 1) statistically significant but not clinically meaningful or 2) clinically meaningful but not statistically significant. In these cases, discussion with FDA is advised.

Figure 4: Recommendations for Submitting and Reporting Subgroup-Specific Participation and Outcome Information



* Discuss how clinically meaning differences across subgroups may contribute to differences in benefit-risk profile in certain subpopulations.

Note: The term “submit” refers to information submitted to the FDA for analysis. The term “report” refers to information that should be included in publically available documents (e.g., labeling, SSED).